CIDP Efficacy and Safety

Hizentra was proven effective and safe in the largest CIDP study conducted to date

First and Only FDA-Approved Subcutaneous Ig for CIDP maintenance
Largest study in CIDP
Total Hizentra Infusions

See the PATH Study design5

Hizentra was evaluated in PATH: the largest CIDP study5*

CIDP PATH Study chart CIDP PATH Study chart
*Study design: Data from a randomized, multicenter, double-blind, placebo-controlled, parallel-group, phase III study of 2 doses of weekly Hizentra versus placebo for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)—the PATH Study. Subjects who relapsed during the postrandomized phase were to receive IgPro10 as a rescue medication within 1 week.

CIDP and the PATH study

Watch a summary of Dr. Jeffrey A. Allen's talk from the 2018 AANEM conference, where he discusses the PATH trial.

Frequently asked questions about Hizentra for CIDP

Want to know more about Hizentra? See answers to many prescribers' frequently asked questions.

Frequently asked questions about CIDP
Flexibility with Hizentra self-administration for CIDP

Create personalized treatment plans to meet your patients' clinical needs and personal preferences.

See why Hizentra may be right for your patients
You are now leaving the current website.

Do you want to continue?

No Yes